HC Wainwright keeps Buy on Genmab stock at USD 40 target

Published on 10/01/2026 at 09:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 25.06 percent to USD 2.05 billion in the first half of 2026. Genmab stock costs EUR 310.65 on October 1, 2026, versus EUR 314.50.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab A/S (ISIN DK0010272202) was trading at EUR 310.65 at Lang & Schwarz on October 1, 2026 at 9:12 a.m. CEST, down 1.22 percent versus the prior close of EUR 314.50 on September 30, 2026. According to Investing.com on September 14, 2026, H.C. Wainwright reiterated a Buy rating and a USD 40.00 price target.

Revenue growth stays visible

MetaTrader reports that revenue reached USD 2.051 billion in the six months ended June 30, 2026, compared with USD 1.640 billion in the same period of 2025. That is a calculated increase of 25.06 percent, while adjusted operating profit rose to USD 656.00 million from USD 554.00 million, an increase of 18.41 percent.

The earnings mix is important because royalty revenue reached USD 1.708 billion in the first half of 2026, while EPKINLY net sales rose 48.00 percent to USD 312.00 million. The figures point to a broader contribution from commercial products alongside Genmab's established royalty base.

Guidance meets balance-sheet pressure

For the full year 2026, the report cited revised revenue guidance of USD 4.325 billion to USD 4.525 billion and adjusted operating profit guidance of USD 1.065 billion to USD 1.385 billion. The same report put total borrowings at USD 5.135 billion after the Merus acquisition, compared with zero in the prior-year period, making debt service a central counterweight to the growth profile.

Net profit for the first half of 2026 was USD 356.00 million, down 32.96 percent from USD 531.00 million in the first half of 2025. Operating cash flow also fell to USD 54.00 million from USD 349.00 million, so revenue growth has not translated into an equally strong cash conversion trend.

Next dates and market position

OnVista lists an extraordinary general meeting for October 7, 2026 and the third-quarter 2026 report for November 5, 2026. The scheduled results date gives the market a defined next checkpoint for the revenue outlook, pipeline spending and the effects of acquisition financing.

Market data put Genmab's market capitalization at USD 21.9 billion as of September 30, 2026, with a 52-week range of USD 23.62 to USD 35.90. The euro quote is a separate Lang & Schwarz reference for German-market investors and is not combined with the Nasdaq quotation.

Genmab stock holds a defined catalyst calendar

Genmab stock was trading at EUR 310.65 at Lang & Schwarz on October 1, 2026 at 9:12 a.m. CEST, down 1.22 percent versus the Lang & Schwarz prior close of EUR 314.50 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Genmab stock.